Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use by Tumor Type, According to Spherix Global Insights

Summary

Oncologists are increasingly incorporating subcutaneous PD-1 inhibitors into disease-specific treatment strategies rather than viewing them solely as convenient alternatives to intravenous administration, according to Spherix Global Insights analysis.